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What is NMS?
Neuroleptic malignant
syndrome (NMS) is a rare
disease occurring from an
adverse reaction to antipsychotic use. The diagnosis
and predictability of the disease
is extremely difficult as it mimics
other syndromes (Margetić &
Aukst-Margetić, 2010). The
disease onset can occur when
initiating medications,
escalating doses, or adding an
adjunctive anti-psychotic to the
regimen. Although causing the
unpredictability, the disease can
occur at any dose (Paul,
Michael, John, & Lenox, 2012).
Further increasing the difficulty
of diagnostics, signs and
symptoms are very wide spread.
The Diagnostic and Statistical
Manual of Mental Disorders
created a tool to assist in the
clinical setting; it, “requires the
presence of 2 core features of
severe muscle rigidity and
elevated temperature after
recent initiation or change in
dosage of an antipsychotic,
along with 2 or more of the
following symptoms:
diaphoresis, dysphagia, tremor,
incontinence, changes in level of
consciousness, mutism,
tachycardia, elevated or labile
blood pressure, leukocytosis,
and elevated creatine kinase
(CK) levels” (Paul, Michael, John,
& Lenox, 2012). The basis of
diagnostics have been primarily
through simple exclusion of
other syndromes and diseases.
With this being said the biggest
factor in decreasing the severity
of NMS is disease timely
diagnosis and treatment.

The pathophysiology of NMS is not completely
understood, but there are theories and assumptions that
have been found. The major dysfunction is thought to be
due to sudden and profound decrease in dopamine D2
receptor blockade (Paul, Michael, John, & Lenox, 2012).

NMS: Devastating Effects
NMS although rare can be fatal. NMS has a spectrum of
severity from minor to severe. It has been shown in
evidence based practice that if NMS if diagnosed and
treated early enough can drastically reduce the
severity (McDermott, Noordsy, & Traum, 2013). It is
important for clinicians and patients to watch for these
signs and symptoms when escalating doses of
antipsychotic medications or adding new or adjunctive
antipsychotics. Those that live with the patients taking
antipsychotics also need education to watch for these
trigger signs.

Clinical Course
Altered level of
consciousness

Depiction of a case with NMS
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Signs and
Symptoms

Theory of pathophysiology

Muscle rigidity

Dopamine blockade in the
nigrostriatal region

Elevated or
labile blood
pressures

Autonomic dysregulation of
norepinephrine, serotonin,
epinephrine; Dopamine is thought
to play a role in interrupting the
inhibitory pathways of the
sympathetic nervous system
(Margetić & Aukst-Margetić, 2010)

Elevated CPK

Muscle rigidity, rhabdomyolysis,
agitation, physical muscle injury

Elevated
temperature

Severe muscle rigidity, decreased
dopamine in the hypothalamus
(temperature control center of
brain)

(Paul, Michael, John, & Lenox, 2012)

Elevated CPK

Effects
Requirements of
mechanical ventilation
and use of restraints
(Hashim, Zeb-un-Nisa,
Alrukn, & Al Madani,
2014)
Acute renal failure

Dysphagia

Risk for aspiration and
long term NPO status
leading to malnutrition

Diaphoresis

Skin breakdown

Labile blood pressure

Circulatory collapse and
death
Muscle rigidity and
Risk for deep vein
bradykinesia
thrombosis, skin
breakdown,
rhabdomyolysis
Elevated temperatures
MRI imagine has shown
damage to cerebellar and
basal ganglia due to
breakdown of membrane
lipid, protein
denaturation, and
mitochondrial
dysfunction (Lyons, &
Cohen, 2013).
It is imperative for nursing to prevent secondary effects
through appropriate positioning, hydration, frequent turning,
close monitoring of vital signs and respiratory status, and
daily skin assessments to name a few precautions.

The Dilemma In Conclusion
NMS has been a dilemma in the medical field. The pathophysiology has not been fully discovered. Diagnosis is rather
difficult through mimicking of other syndromes and diseases. Types of treatments are controversial while standard medical
practice has not been developed yet. The onset is unpredictable occurring at any dose. Standard practice for escalating
doses of antipsychotic medication has only been made for a few such as quetiapine and clozapine (Langan, Martin,
Shajahan, & Smith, 2012). After recovery re-challenging antipsychotic medication is still under debate. NMS is rare and
typically self-limiting within 7-10 days if the antipsychotic medication is discontinued (Hashim, Zeb-un-Nisa, Alrukn, & Al
Madani, 2014). Although there are those cases that are severe enough to cause respiratory and cardiovascular
compromise. Nevertheless there is some information through evidence based practice that is certain. Those with history
of NMS are to be treated with single oral antiphyschotic medication with low doses and escalating as slow as possible
(Ouyang & Chu, 2013). There is a much greater risk with using intravenous or intramuscular routes (Yanfen, Yahui, & Aiguo,
2014). Lastly and most important to note is that fast recognition and treatment have been proven to decrease the severity
of symptoms.
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